PRF Technologies Ltd（PRFX）股票分析

AI 分析 of PRF Technologies Ltd (PRFX)

持有

PainReform Ltd (PRFX) is not a good buy right now due to significant financial losses and high volatility. The current price is $0.85, and the stock has a 1-year change of -81.86%, indicating a substantial decline over the past year. While the recent 5-day change of +16.01% shows some short-term recovery, the overall trend and financial performance suggest caution. The RSI is at 73.416, indicating that the stock is overbought, which could lead to a price correction. Additionally, the forward P/E ratio is 0, reflecting uncertainty about future earnings, and the gross margin has been negative, with figures like -4776.47% in Q4 2025. The main risk is the high volatility and the potential for further declines, as evidenced by the 52-week low of $0.64.

估值指标

PRF Technologies Ltd（PRFX）当前预期市盈率为 0.00，5 年平均预期市盈率为 -1.93。

预期市盈率

合理

5 年均值 P/E

-1.93

当前P/E

0.00

高估

0.72

低估

-4.59

预期 EV/EBITDA

严重低估

5 年均值 EV/EBITDA

0.00

当前EV/EBITDA

0.00

高估

0.00

低估

0.00

预期市销率

严重低估

5 年均值 P/S

0.00

当前P/S

0.00

高估

0.00

低估

0.00

Alphio AI 对 PRFX 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重（25 / 50 / 25），不构成保证。

乐

乐观

乐观 · 25%PRFX

$1.94

情景价格

基

基准

基准 · 50%PRFX

$1.75

情景价格

悲

悲观

悲观 · 25%PRFX

$1.65

情景价格

PRFX 常见问题 —— 由 Alphio AI 解答

PRF Technologies Ltd is an Israel-based company engaged primarily in pharmaceutical sector. The Company is a producer of speciality pharmaceuticals as well as energy analytics powered by artificial intelligence (AI). The Firm develops reformulated and sustained‑release drug‑delivery platforms that combine proven generic medicines with proprietary extended‑release systems to improve patient outcomes. One of the Company's products is PRF‑110 - a ropivacaine‑based formulation designed to deliver localised, extended postoperative analgesia. The Company also advances OcuRingTD, a bio‑erodible drug‑release ring integrated with intraocular lenses for continuous delivery of medications in cataract surgery.In the energy analytics sector the Company operates DeepSolar platform that provides AI‑powered monitoring, forecasting, and optimisation tools for solar asset performance. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

PainReform Ltd (PRFX) is not a good buy right now due to significant financial losses and high volatility. The current price is $0.85, and the stock has a 1-year change of -81.86%, indicating a substantial decline over the past year. While the recent 5-day change of +16.01% shows some short-term recovery, the overall trend and financial performance suggest caution. The RSI is at 73.416, indicating that the stock is overbought, which could lead to a price correction. Additionally, the forward P/E ratio is 0, reflecting uncertainty about future earnings, and the gross margin has been negative, with figures like -4776.47% in Q4 2025. The main risk is the high volatility and the potential for further declines, as evidenced by the 52-week low of $0.64.